ArticleFrontiers in nutrition2024
Association between serum pyridoxal 5'-phosphate levels and chronic obstructive pulmonary disease: findings based on NHANES 2005-2010.
Article in Frontiers in nutrition, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Vitamin B6 is involved in regulating a variety of biological reactions in cell metabolism, and possesses antioxidant and anti-inflammatory biological functions. 5'-pyridoxal phosphate (PLP) is the main biologically active form of vitamin B6. There is currently no research on the correlation between serum PLP levels and chronic obstructive pulmonary disease (COPD) prevalence. This study aims to explore the relationship between serum PLP levels and COPD prevalence. Methods: This cross-sectional study included adult participants with complete data on COPD diagnosis and serum PLP levels from 2005 to 2010 National Health and Nutrition Examination Survey (NHANES) database. Generalized linear model (GLM) was employed to analyze the association between serum PLP levels and COPD prevalence. The restricted cubic spline (RCS) curve and threshold effect analysis were used to explore the potential non-linear relationship between serum PLP levels and COPD prevalence. Subgroup analysis was carried out to assess the robustness of the relationship between serum PLP levels and COPD prevalence. Results: A total of 11,103 participants were included in this study, of whom 830 were diagnosed with COPD. Higher PLP levels are associated with a reduced prevalence of COPD. GLM analysis confirmed that the groups with higher PLP levels (Q3 and Q4) had a significantly lower prevalence rate of COPD compared to the group of Q2. The RCS curves showed a non-linear "L"-shaped relationship between serum PLP levels and COPD prevalence. The threshold effect analysis found a critical point of 43.3 nmol/L. When serum PLP level is below 43.3 nmol/L, there is a negative correlation between serum PLP levels and COPD prevalence ( Conclusion: This study is the first to discover a non-linear relationship between serum PLP levels and COPD prevalence. Higher serum PLP levels are associated with a reduced prevalence of COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.